Por: RTTNews Health November 27, 2023
GSK plc (,) reported positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma. The company said the trial met primary endpoint of progression-free survival and showed that belantamab mafodotin when combined with bortezomib plus dexamethasone significantly extended the time to disease... + full article
Orlando Sentinel USA Sports March 29, 2023
Lake Brantley 9, Seminole 6 (8 inn.) Buzz: Jackson Golden went 2-for-5 with 2 home runs and 6 RBI for Lake Brantley. Ben Colley had a home run. Bryce Carter had 2 hits for Seminole. Mount Dora Christian Academy 10, Oak Hall (Gainesville) 4 Buzz: Collin Priest went 5-for-5 with a... + más
NFL Playoff Scenarios | ABC News
Le Krewe du Roi celebrates the state at 58th annual Mardi Gras Ball | The Advocate
Orlando Sentinel USA Sports March 25, 2023
Orangewood Christian 11, The Master’s Academy 1 Buzz: Austin Waring threw 5 innings of 1-run ball (0 earned runs) while allowing 4 hits and striking out 8 for Orangewood Christian. He lowered his season ERA to 0.78. Aiden McKee went 3-for-3 with a double, a walk, an RBI and a... + más
Time USA Health March 03, 2023
GSK Plc’s vaccine for won the support of a key panel of U.S. regulatory advisers for use in people aged 60 and older, as the drugmaker races against Pfizer Inc. to bring to market the first vaccine for RSV. The panel of 12 outside advisers to the Food and Drug Administration... + más
FDA advisors recommend GSK's RSV vaccine for older adults, but flag potential safety risks | CNBC
GSK vaccine for older adults granted FDA priority review | Fox Business
CNBC USA Health March 01, 2023
watch nowVIDEO1:5501:55FDA advisory panel votes in favor of adult RSV vaccine from GSK PLCThe Food and Drug Administration's independent panel of advisors on Wednesday recommended RSV vaccine for adults ages 60 and older, though they flagged potential safety issues over... + más
FDA Panel Backs GSK’s RSV Vaccine for Older People | Time
MarketWatch USA Business February 01, 2023
Operating profit increased to GBP1.87 billion from GBP492 million in the fourth quarter of 2021, reflecting fair-value gains on investments, milestone income from disposals and lower remeasurement charges for contingent consideration liabilities, GSK said. After-tax profit also... + más
GSK 4Q Sales and Earnings Rose, Driven by Specialty Medicines, Vaccines -- Update | MarketWatch
Fox Business USA Business November 02, 2022
Check out what's clicking on FoxBusiness.com GSK opened 2% higher in U.S. trading Wednesday but closed down 2%. Shares rose after the drugmaker reported financial results that beat Wall Street forecasts and announced the Food and Drug Administration had accepted a biologics... + más
GSK Raises 2022 Guidance as 3Q Sales Beat Expectations -- Update | MarketWatch
About iurex | Privacy Policy | Disclaimer |